Skip to main content
SpringerLink
Log in
Book cover

Cornea and External Eye Disease pp 109–122Cite as

Current Systemic Immunosuppressive Strategies in Penetrating Keratoplasty

  • Chapter

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allison A, Hovi R, Watts A, Webster A (1977) The role of de novo purine synthesis in lymphocyte transformation. CIBA Found Symp 48:207

    CAS  PubMed  Google Scholar 

  2. Benelli U, Lepri A, Del-Tacca M, Nardi M (1996) FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther 12(4):425–431

    CAS  PubMed  Google Scholar 

  3. Birnbaum F, Reinhard T, Bohringer D, Sundmacher R (2005) Endothelial cell loss after autologous rotational keratoplasty. Graefes Arch Clin Exp Ophthalmol 243(1):57–59

    Article  PubMed  Google Scholar 

  4. Brattstrom C, Tyden G, Sawe J, Herlenius G, Claesson K, Groth CG (1996) A randomized, doubleblind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 28(2):985–986

    CAS  PubMed  Google Scholar 

  5. Bussutil RW, Holt CD (1997) Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant Proc 29:534–538

    Google Scholar 

  6. Chen YF, Gebhardt BM, Reidy JJ, Kaufman HE (1990) Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 109(2):132–137

    CAS  PubMed  Google Scholar 

  7. Crowe A, Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15(11):1666–1672

    Article  CAS  PubMed  Google Scholar 

  8. Deierhoi M, Sollinger H, Diethelm A et al. (1993) One-year follow-up results of a phase 1 trial of mycophenolate mofetil (RS-61443) in cadaveric renal transplantation. Transplant Proc 25:693f

    Google Scholar 

  9. Dickey JB, Cassidy EM, Bouchard CS (1993) Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. Cornea 12(3):204–207

    CAS  PubMed  Google Scholar 

  10. Eisen HJ, Tuzcu EM, Dorent R et al. (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847–858

    Article  CAS  PubMed  Google Scholar 

  11. European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. Lancet 345:1321–1325

    Google Scholar 

  12. Mayer K, Birnbaum F, Reinhard T, Reis A, Braunstein S, Claas F, Sundmacher R (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88(7):915–919

    Article  CAS  PubMed  Google Scholar 

  13. Hikita N, Lopez JS, Chan C, Mochizuki M, Nussenblatt RB, de Smet MD (1997) Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 38:901–909

    CAS  PubMed  Google Scholar 

  14. Hill JC, Maske R (1988) An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 46(1):26–30

    CAS  PubMed  Google Scholar 

  15. Hill JC (1995) Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye 9(4):422–428

    PubMed  Google Scholar 

  16. Hoffmann F, Wiederholt M (1986) Topical cyclosporin A in the treatment of corneal graft reaction [editorial]. Cornea 5(3):129

    CAS  PubMed  Google Scholar 

  17. Kino T, Hatayama H, Hashimoto M et al. (1987) FK-506, a novel immunosuppressant isolated from Streptomyces: 1. Fermentation, isolation, and physio-chemical and biological characteristics. J Antibiot 40:1249–1255

    CAS  PubMed  Google Scholar 

  18. Lakkis FG, Arakelov A, Koniecny BT, Inoue Y (2000) Immunologic “ignorance” of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 6:686–688

    Article  CAS  PubMed  Google Scholar 

  19. Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R (2003) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 241(12):1051–1054

    Article  CAS  PubMed  Google Scholar 

  20. Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R (2003) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 241(12):1051–1054

    Article  CAS  PubMed  Google Scholar 

  21. Mayer K, Birnbaum F, Reinhard T, Reis A, Braunstein S, Claas F, Sundmacher R (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88(7):915–919

    Article  CAS  PubMed  Google Scholar 

  22. Mills RA, Jones DB, Winkler CR, Wallace GW, Wilhelmus KR (1995) Topical FK-506 prevents experimental corneal allograft rejection. Cornea 14(2):157–160

    CAS  PubMed  Google Scholar 

  23. Minamoto A, Sakata H, Okada K, Fujihara M (1995) Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty. Jpn J Ophthalmol 39(1):12–19

    CAS  PubMed  Google Scholar 

  24. Morris R, Hoyt E, Murphy P (1990) Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T-and B-cell purine synthesis. Transplant Proc 22:1659

    CAS  PubMed  Google Scholar 

  25. Morris RE, Huang X, Gregory CR, Billingham ME, Rowan R, Shorthouse R, Berry GJ (1995) Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 27(3):2068–2069

    CAS  PubMed  Google Scholar 

  26. Murgia MG, Jordan S, Kahan BD (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49(1):209–216

    CAS  PubMed  Google Scholar 

  27. Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ (1994) Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 112(11):1471–1475

    CAS  PubMed  Google Scholar 

  28. Otto Ch, Ulrichs K (2004) The immunology of allograft rejection. Tx Med 16:158–171

    Google Scholar 

  29. Perry HD, Donnenfeld ED, Acheampong A, Kanellopoulos AJ, Sforza PD, D’Aversa G, Wallerstein A, Stern M (1998) Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J 24(3):159–165

    CAS  PubMed  Google Scholar 

  30. Reinhard T, Bohringer D, Enzmann J, Kogler G, Wernet P, Bohringer S, Sundmacher R (2004) HLA class I/II matching and chronic endothelial cell loss in penetrating normal risk keratoplasty. Acta Ophthalmol Scand 82(1):13–18

    Article  PubMed  Google Scholar 

  31. Reinhard T, Kontopoulos T, Wernet P, Enzmann J, Sundmacher R (2004) Long-term results of homologous penetrating limbokeratoplasty in total limbal stem cell insufficiency after chemical/thermal burns. Ophthalmologe 101(7);682–687

    Article  PubMed  Google Scholar 

  32. Reinhard T, Moller M, Sundmacher R (1999) Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A. Cornea 18(6):645–651

    CAS  PubMed  Google Scholar 

  33. Reinhard T, Sundmacher R, Godehardt E, Heering P (1997) [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor.] Systemische Cyclosporin-A-Prophylaxe nach Keratoplastiken mit erhohtem Risiko für Immunreaktionen als einzigem erhohten Risikofaktor. Ophthalmologe 94(7):496–500

    Article  CAS  PubMed  Google Scholar 

  34. Reinhard T, Sundmacher R (1996) Local cyclosporin A therapy in Thygeson superficial punctate keratitis — a pilot study. Klin Monatsbl Augenheilkd 209(4):224–227

    CAS  PubMed  Google Scholar 

  35. Reinhard T, Sundmacher R (1992) Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A — a retrospective study of 18 patients. Klin Monatsbl Augenheilkd 201(3):159–163

    CAS  PubMed  Google Scholar 

  36. Reinhard T, Sundmacher R (1999) Topical cyclosporin A in Thygeson’s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol 237(2):109–112

    Article  CAS  PubMed  Google Scholar 

  37. Reis A, Megahed M, Reinhard T, Braunstein C, Godehardt E, Sundmacher R (2001) RAD, a new immunosuppressive macrolide in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol 239(9):689–692

    CAS  PubMed  Google Scholar 

  38. Reis A, Megahed M, Reinhard T, Godehardt E, Braunstein C, Sundmacher R (2002) Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea 21(1):81–84

    Article  PubMed  Google Scholar 

  39. Reis A, Megahed M, Reinhard T, Godehardt E, Spelsberg H, Braunstein C, Sundmacher R (2000) Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 70(9):1397–1401

    CAS  PubMed  Google Scholar 

  40. Reis A, Reinhard T, Sundmacher R, Althaus C, Voiculescu A, Kutkuhn B (1998) [Mycophenolate mofetil in ocular immunological disorders. A survey of the literature with 3 case reports]. Mycophenolatmofetil (CellCept) bei okularen immunologischen Störungen. Literaturübersicht mit 3 Kasuistiken. Klin Monatsbl Augenheilkd 213(5):257–261

    CAS  PubMed  Google Scholar 

  41. Reis A, Reinhard T, Sundmacher R, Braunstein C, Godehardt E (1998) Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 82:700–703

    CAS  PubMed  Google Scholar 

  42. Reis A, Reinhard T, Sundmacher R, Godehard E, Braunstein C (1998) A comparative investigation of the effect of FK506 (Prograf®) and Cyclosporin A (Sandimmun®, CSA) in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol 236:785–789

    Article  CAS  PubMed  Google Scholar 

  43. Reis A, Reinhard T, Sundmacher R, Godehard E, Braunstein C (1998) FK506 and mycophenolate mofetil: two novel immunosuppressants in murine corneal transplantation. Transpl Proc 30(8)

    Google Scholar 

  44. Reis A, Reinhard T, Voiculescu A, Kutkuhn B, Godehardt E, Spelsberg H, Althaus C, Sundmacher R (1999) Mycophenolatemofetil versus cyclosporin A in high-risk keratoplasty patients: a prospectively randomized clinical trial. Br J Ophthalmol 83:1268–1271

    CAS  PubMed  Google Scholar 

  45. Sawada S, Suzuki G, Kawase Y, Takaku F (1987) Novel immunosuppressive agent, FK-506: in vitro effects on the cloned T cell activation. J Immunol 40:1249–1255

    Google Scholar 

  46. Schmitz K, Hitzer S, Behrens-Baumann W (2002) Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe 99(1):38–45

    CAS  PubMed  Google Scholar 

  47. Schuurman HJ, Schuler W, Ringers J, Jonker M (1998) The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 30(5):2198–2199

    CAS  PubMed  Google Scholar 

  48. Simmons WD, Rayhill SC, Sollinger HW (1997) Preliminary risk-benefit assessment of mycophonlate mofetil in transplant rejection. Drug Safety 17(2):75–92

    CAS  PubMed  Google Scholar 

  49. Sloper CM, Powell RJ, Dua HS (2001) Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts; Ophthalmology 108(10):1838–1844

    Article  CAS  PubMed  Google Scholar 

  50. Streilein JW, Okamoto S, Sano Y, Taylor AW (2000) Neural control of ocular immune privilege. Ann NY Acad Sci 917:297–306

    CAS  PubMed  Google Scholar 

  51. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophonlate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61(7):1029–1037

    Google Scholar 

  52. Thompson P, Xu D, Brunette I, Chen H (1998) Combined effect of rapamycin and cyclosporine in the prevention of rat corneal allograft rejection. Transplant Proc 30(4):1033–1035

    Article  CAS  PubMed  Google Scholar 

  53. Vu MD, Qi S, Xu D, Wu J, Peng J, Daloze P, Sehgal S, Leduc B, Chen H (1998)Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart,pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 66(12):1575–1580

    CAS  PubMed  Google Scholar 

  54. Woodle ES, Thistlethwaite JR, Gordon JH for the FK506 Kidney Transplant Rescue Study Group (1996) A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 62:594–599

    CAS  PubMed  Google Scholar 

  55. Yoshimura N, Matsui S, Hamashima T, Oka T (1989) Effects of a new immunosuppressive agent, FK-506, on human lymphocyte responsiveness in vitro: 1: Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 47:351–356

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reis Medical Institution Est., Landstrasse 310, 9495, Triesen, Principality of Liechtenstein

    Alexander Reis (Priv.-Doz. Dr.)

  2. University Eye Hospital, Killianstrasse 5, 79106, Freiburg, Germany

    Thomas Reinhard (Prof. Dr.)

Authors
  1. Alexander Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Reinhard
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Eye Hospital, Killianstrasse 5, 79106, Freiburg, Germany

    Thomas Reinhard MD (Professor of Ophthalmology) (Professor of Ophthalmology)

  2. Cornea & External Diseases Service, Moorfields Eye Hospital, London, EC1V 2PD, UK

    D.F.P. Larkin MD, MRCPF, FRCS

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Reis, A., Reinhard, T. (2006). Current Systemic Immunosuppressive Strategies in Penetrating Keratoplasty. In: Reinhard, T., Larkin, D. (eds) Cornea and External Eye Disease. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31226-9_9

Download citation

  • DOI: https://doi.org/10.1007/3-540-31226-9_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22600-0

  • Online ISBN: 978-3-540-31226-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation